Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease by Benoît Rive et al.
REVIEW ARTICLE
Synthesis and Comparison of the Meta-Analyses Evaluating
the Efficacy of Memantine in Moderate to Severe Stages
of Alzheimer’s Disease
Benoıˆt Rive • Serge Gauthier • Sophie Costello •
Caroline Marre • Cle´ment Franc¸ois
Published online: 14 June 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract The N-methyl-D-aspartate receptor antagonist,
memantine, is licensed for the treatment of moderate to
severe Alzheimer’s disease (AD). Memantine is adminis-
tered both as a monotherapy and as an add-on therapy in
patients already receiving acetylcholinesterase inhibitors.
Several meta-analyses have been published that examine
the efficacy of memantine in the treatment of AD, based on
clinical trial data. However, different disease severities and
concomitant medication use in the trial populations means
that synthesis of this data is challenging with numerous
methodological decisions required. The main objectives of
this study were to review the methodologies of different
meta-analyses, assess the impact of specific methodologi-
cal approaches on efficacy results, and to help interpret
previous meta-analyses results concerning the efficacy of
memantine in moderate to severe stages of AD. The
methodologies of five meta-analyses were reviewed in
terms of the included trials, combination of data, choice of
outcome, and analysis methods. Results were extracted and
compared in line with the methodological approach taken.
The most robust results were observed on cognition,
activities of daily living, and overall assessment, where
memantine showed a consistent benefit over placebo.
The benefit of memantine on behavioral symptoms was
also demonstrated, but results were more heterogeneous.
Variability could not be explained by baseline severity and
concomitant treatment alone. It is stressed that interpreta-
tion of meta-analysis results must be considered within the
context of the methodological approach. Overall, results
from individual clinical trials and from meta-analyses
demonstrate that memantine represents a valuable treat-
ment option in AD.
1 Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder characterized by a gradual loss of cognitive
function and ability to perform activities of daily living
(ADL) [1, 2]. Behavioral and psychological symptoms can
emerge, including physical aggression, restlessness, inap-
propriate social behaviors, and agitation, with behavioral
symptoms worsening as the disease progresses [3]. Cog-
nition, function and behavioral domains can all be assessed
individually, with the Committee for Medicinal Products
for Human Use (CHMP) also recommending that symp-
tomatic improvements be assessed using a global assess-
ment of response [4].
The burden of AD is expected to increase with the aging
population, with an anticipated 115 million people globally
living with dementia by 2050 [5]. AD is associated with a
substantial economic burden. The total annual cost of
dementia across Europe in 2010 was estimated to be
€105.2 billion, accounting for 13 % of the costs for all
brain disorders [6].
To date, there is no cure available for AD and prevention
of further worsening of symptoms represents the most real-
istic treatment goal [7, 8]. Memantine is a moderate-affinity,
B. Rive (&)  C. Marre  C. Franc¸ois
Global Outcomes Research Division, Lundbeck SAS,




Alzheimer’s Disease Research Unit, McGill Centre
for Studies in Aging, Montre´al, QC, Canada
S. Costello
Costello Medical Consulting Limited, Cambridge, UK
CNS Drugs (2013) 27:573–582
DOI 10.1007/s40263-013-0074-x
noncompetitive, voltage-dependent N-methyl-D-aspartate
receptor antagonist with fast on–off kinetics [9]. It is
licensed for the treatment of moderate to severe AD, rep-
resented by patients with a mini mental state examination
(MMSE) score of \20 [10]. Memantine can be used in
treatment-naı¨ve patients and patients withdrawn from
acetylcholinesterase inhibitors (AChEIs), or as an add-on
treatment in patients already stabilized on an AChEI, most
commonly donepezil.
The efficacy of memantine has been evaluated in several
clinical trials, with memantine assessed both as a mono-
therapy [11–14] and as an add-on therapy in patients
already receiving AChEIs [15, 16]. Improvements in AD
domains versus placebo showed considerable variation in
whether these outcomes were significantly improved.
Meta-analysis of the data from several clinical trials is
needed to understand the efficacy of memantine based on a
pooled analysis. However, as a result of the heterogeneity
of the trial populations, synthesis of the meta-analysis data
can be challenging with numerous methodological deci-
sions required.
Several meta-analyses have been published that aimed
to provide conclusions on the efficacy of memantine in the
treatment of AD from clinical trials. The objective of this
article is to review the methodologies of these analyses, to
assess the impact of different approaches on the pooled
results, and to generate general conclusions on the efficacy
of memantine in AD.
2 Published Meta-Analyses of Memantine Data
Five meta-analyses of memantine data are considered.
This selection does not stem from a systematic literature
review but was aimed at covering a wide range of
approaches (for the selection of studies, patient popula-
tions, analysis strategy, and analysis method) and authors,
but also based on a similar availability of evidence. In
2006, the Cochrane Collaboration published a meta-anal-
ysis of memantine in AD, vascular dementia, and mixed
dementia [1]. A meta-analysis published in 2007 by
Winblad was conducted during the European regulatory
process when the memantine license was extended from
moderately severe to severe patients, to also include
patients with moderate AD [2]. The meta-analysis pub-
lished in 2007 by Doody considered the overall efficacy
and safety of memantine across the spectrum of AD
severity [17]. Meta-analyses have also been conducted as
part of national health technology assessments. In 2009,
the German Institute for Quality and Efficiency in Health
Care (IQWiG) published their evaluation report on me-
mantine in AD [18]. In 2010, as part of the National
Institute for Health and Clinical Excellence (NICE)
review of AD therapies, the independent Peninsula
Technology Assessment Group (PenTAG) conducted a
systematic review and meta-analysis [19].
All five meta-analyses incorporated data from the clin-
ical development program for memantine in AD. This
comprised six randomized, double-blind, placebo-con-
trolled trials of 6 months duration, designed in line with
current recommendations of the European Medicines
Agency (EMA). The trials assessed the efficacy of me-
mantine across key AD domains (cognition, ADL, global
assessment, and behavior) using standard scales. The
methodologies of the trials were similar but with important
differences in the included patient populations, both in
terms of AD severity and background treatment with
AChEIs (Table 1). Another important point is that in dis-
tinct populations of varying severities, different scales are
sometimes used to measure the same concept. For example,
both the Alzheimer’s disease assessment scale-cognitive
subscale (ADAS-cog) and severe impairment battery (SIB)
are used to assess cognition.
While these six pivotal registration studies were the
main data sources, not all meta-analyses included all trials.
Furthermore, one additional trial conducted more recently
was included in the meta-analysis conducted by IQWiG:
Lu-10116, the pivotal trial for the authorization of me-
mantine in China, assessed memantine as a monotherapy in
Chinese patients with moderate to severe AD over a
4-month period [20].
2.1 Cochrane
This meta-analysis included the six pivotal trials and uti-
lized only data available in the primary publications with
no posthoc analyses [1]. Analyses were conducted sepa-
rately for trials in patients with moderately severe to severe
AD, and with mild to moderate AD. The meta-analysis
does not present a summary that encompasses the total
licensed population for memantine, and the second analysis
includes off-label use.
2.2 Winblad
This meta-analysis included all six pivotal clinical trials
[2]. In accordance with the indication for memantine, only
moderate AD patients from the clinical trials that included
mild to moderate AD patients were included in the meta-
analyses, and patients with mild AD were excluded. As
part of the evidence dossier prepared by NICE, the man-
ufacturer of memantine (Lundbeck) undertook an interac-
tion analysis using the same set of studies and the same
analysis population as in the Winblad meta-analysis to
ascertain the impact of baseline disease severity and prior
or concomitant AChEI use [21].
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2.3 Doody
As with the Cochrane and Winblad publications, this
included the six pivotal clinical trials for memantine [17].
The entire population from these trials were included, with
mild AD representing off-label use considered.
2.4 IQWiG
The IQWiG meta-analysis included the six pivotal trials plus
clinical trial Lu-10116 [20]. In line with the memantine
indication, mild patients were excluded. In the meta-analysis,
severe patients from study MEM-MD-02 [15] were excluded
because donepezil is not indicated in this group.
2.5 PenTAG
This analysis considered trials for memantine as mono-
therapy and as combination therapy separately [19].
In monotherapy, studies MRZ-9605 [11] and MEM-MD-01
[12] were included. Trials Lu-99679 [13] and MEM-MD-
10 [14] were excluded on the basis that they included mild
off-label use patients. Furthermore, posthoc analyses of
moderate AD patients from these trials were not considered
by PenTAG to be reported in sufficient detail to allow their
inclusion in meta-analyses. In the combination analysis,
trials MEM-MD-02 [15] and MEM-MD-12 [16] were
considered. Study MEM-MD-12 included patients with
mild to moderate disease. There was therefore a lack of
consistency between the analysis of the monotherapy and
combination trials, with the exclusion of trials in patients
with mild to moderate AD for monotherapy yet the inclu-
sion of these trials in the combination analysis. This
inconsistency was highlighted by Lundbeck during the
NICE review process [21]. The inclusion of study
MEM-MD-12 in the combination analysis was justified by
PenTAG based on the MMSE score upper range at baseline
being 20.37 [22]. PenTAG stated that as this value was
Table 1 Overview of the design of memantine clinical trials
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only minimally over 20 (the threshold for moderate
disease) the study could be included. However, this justi-
fication does not explain the discrepancy in approach
between the monotherapy and combination analyses.
Figure 1 provides the MMSE scores at baseline in the
MEM-MD-10 and MEM-MD-12 studies. The cutoff used
by PenTAG to exclude MEM-MD-10 was at least 20 % of
patients with mild disease. However, the patients included
in the two studies had very similar disease severities at
baseline with both above the 20 % threshold: 32.5 % of
patients in MEM-MD-10 had mild AD at baseline com-
pared to 30.4 % in MEM-MD-12. Although the concerns
regarding inconsistency were raised, these were not
amended in the final PenTAG report or the NICE final
appraisal determination [23]. However, for the purpose of
this analysis and to ensure consistency of approach, the
combination results will be based on study MEM-MD-02
only, in line with the approach adopted for the mono-
therapy evaluation.
3 Methodological Issues
Due to the heterogeneous nature of patients in memantine
trials, the synthesis of evidence can be approached in
several ways with a number of key points to consider when
determining the most appropriate analysis. The first deci-
sion relates to the severity of included patients. There are
no studies for memantine that consider the complete
licensed indication only. A selection of trials in the mod-
erately severe to severe patient population only excludes an
assessment of memantine in moderate AD patients above
the moderately severe threshold. The limitation of this
approach is that a proportion of the population
corresponding to the memantine indication are not con-
sidered. For moderate patients to be considered, the trials in
mild to moderate patients must be included in the data
synthesis. If these trials are included in their entirety, the
meta-analysis will consider the use of memantine in mild
AD, which represents off-label use and may make the
analysis less clinically relevant. However, subgroup anal-
ysis of the moderate patients only from the mild to mod-
erate trials represents a posthoc review of data that could
potentially break trial randomization, which was not
stratified on baseline severity. The Cochrane Collaboration
recommend that subgroup analyses in meta-analyses
should be kept to a minimum and only conducted when
there is a clinical rationale [24].
Another methodological decision is the analysis of data
according to the presence or absence of treatment with an
AChEI. Combining data across these populations gives a
greater power to the analysis, but also results in mixing of
distinct and heterogeneous patient groups.
The approach to accounting for missing data must also
be considered. Analysis can be conducted on observed
cases (OC), last observation carried forward (LOCF), or as
reported in the original publications. In general, the LOCF
method is preferred because it is closer to the intent-to-treat
principle and better preserves the original study sample
size. However, in chronic and progressive conditions such
as AD, the LOCF method can, in some cases, artificially
overestimate the efficacy of treatment [25]. For example, if
a patient withdraws from the study, due to the degenerative
nature of AD the LOCF analysis will overestimate the
effect by simulating stability when deterioration is more
likely. Whether the LOCF analysis will overestimate or
underestimate the treatment effect depends on the balance,
timing, and reason of withdrawals between the active and
Fig. 1 Baseline severity scores
(mini mental state examination;
MMSE) in studies MEM-MD-
10 and MEM-MD-12
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control groups. In this case, the pooled withdrawal rate
across the six pivotal trials was lower with memantine than
placebo [2].
The methodological approach of each meta-analysis is
summarized in Table 2. In a meta-analysis, data can be
presented as a mean difference (MD; sometimes referred
to as weighted mean differences) or a standardized mean
difference (SMD). A MD is used when all data being
pooled has been assessed with the same scales and this
represents an absolute effect size. This is generally the
preferred approach because the results are expressed in
terms of the original outcome measures making them easy
to interpret. However, in cases when a single outcome has
been assessed with different measures, the SMD must be
used. This is relevant to AD because there are a number
of different instruments that can be used to measure the
same domain. For example, the ADAS-cog and SIB are
used to assess cognition in mild to moderate AD patients
and in moderately severe to severe AD patients, respec-
tively [26].
An examination of the methodological choices of each
meta-analysis was conducted and the results compared.
The heterogeneity of the results was examined using the I2
measure, which describes the percentage of total variation
across studies that is due to heterogeneity and not chance
[27]. An I2 value of 0 % indicates no heterogeneity while
25, 50, and 75 % are the thresholds for low, moderate, and
high heterogeneity, respectively.
4 Reports of Efficacy from Different Meta-Analyses
The results from the individual meta-analyses are provided
in Table 3, with significant results for memantine com-
pared to placebo highlighted. Heterogeneity is summarized
in Table 4.
Table 2 Summary of methodology used in the meta-analyses
Cochrane Winblad Doody PenTAG IQWiGa
Selection of studies
Included studies MRZ-9605 MRZ-9605 MRZ-9605 MRZ-9605 MRZ-9605
MEM-MD-
01
MEM-MD-01 MEM-MD-01 MEM-MD-01 MEM-MD-01
MEM-MD-
02
MEM-MD-02 MEM-MD-02 MEM-MD-02 MEM-MD-02








Use of posthoc analysis of
subgroups
No Yes No No Yes
Selection of patients
Includes patients across the
licensed population for memantine
Yes Yes Yes No (exclusion of MMSE
14–19)
Yes
Inclusion of off-label patients Yes (MMSE
[19)








Moderately severe to severe AD
and mild to moderate AD







Management scores (MD or SMD) MD SMD SMD MD MD and SMD if
necessary
Management of missing data (OC
or LOCF)






ITT, as reported in
individual studies
ITT, as reported in
individual studies
AD Alzheimer’s disease, ITT intent to treat, LOCF last observation carried forward, MD mean difference, OC observed cases, SMD standardized mean
differenc
a Excluded severe patients (identified as those having a baseline MMSE below 10) from study MEM-MD-02
b Included in original PenTAG analysis but excluded here to ensure consistency between monotherapy and combination analyses
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For cognition, the impact of memantine was significant
versus placebo in the majority of meta-analyses. The effect
size of memantine was greater in the moderately severe to
severe population than in the mild to moderate population,
as highlighted by the Cochrane analysis [1]. In the two
meta-analyses that considered the licensed population for
memantine (Winblad [2] and IQWiG [18]), the results for
cognition were similar. The slight variation can be
explained by the inclusion in the latter of study Lu-10116
and different approaches to selecting data. For cognition,
the grouping or not of trials based on background treatment
had an impact on results. The PenTAG analysis for
monotherapy in moderately severe to severe patients
(MRZ-9605 [11] and MEM-MD-01 [12]) was the only
review for which cognition was not significantly improved
with memantine. There was a substantial difference in
effect between study MEM-MD-01, with no significant
impact of memantine on cognition at week 24, and MRZ-
9605, where results were significant.
When considering the effect of memantine on ADL, the
selection of patients according to severity has some impact
on results. The effect of memantine was consistently sig-
nificant for ADL in moderately severe to severe patients
and was not significant in mild to moderate patients. The
efficacy was significant when the total spectrum of AD
severity was considered (Doody analysis).
The results for memantine on behavioral disturbances
were disparate. There was a significant benefit in moder-
ately severe to severe patients when both monotherapy and
combination trials were considered. In this patient popu-
lation, the efficacy was significant when only combination
trial MEM-MD-02 was considered, and was not significant
in monotherapy studies. The impact on behavior was also
not significant when the entire patient spectrum was con-
sidered, as reported in the Doody analysis. For the licensed
indication, a significant efficacy was reported in the
Winblad analysis, although the authors highlight that
interpretation of the results is limited because the LOCF
analysis demonstrates considerable heterogeneity. This was
the only analysis in the Winblad article that demonstrated
heterogeneity. It is of note that the analysis most similar to
Winblad conducted by IQWiG did not report a significant
benefit for behavior. Discrepancies in the behavior out-
come results do not appear to be easily explained by
methodological differences.
For overall assessment of disease, memantine efficacy
was significant across all meta-analyses and the effect was
generally homogeneous, with the exception of the Coch-
rane analysis in mild to moderate patients. In line with the
results on cognition, the effect with memantine was greater
in the more severe patient population. In the PenTAG
analysis, the efficacy for overall assessment was greater for
memantine as a monotherapy than in combination therapy,
which was based on study MEM-MD-02 only in this case.
For the licensed indication, the effect size of memantine
was reported to be similar in the Winblad and IQWiG
meta-analyses, and again small differences can be
explained by an additional trial included in the latter and
different approaches to data selection.
5 Factors Contributing to Different Results
Patients in the pivotal memantine studies were very het-
erogeneous and meta-analyses can therefore be conducted
in a number of ways. Interpretation of the data must be
considered within the context of the methodological
approach. All approaches are valid and each methodolog-
ical decision is associated with strengths and limitations.
For example, exclusion of mild patients no longer ensures
trial randomization. However, the other approach is to
either include all patients from mild to moderate trials,
Table 4 Summary of heterogeneity assessments in meta-analyses
Heterogeneity
observed for









Monotherapy Combination Moderate to
severe
Cognition No Yes
(I2 = 57 %)
Yes
(I2 = 74 %)
No Yes
(I2 = 86 %)
NA Yes
(I2 = 47 %)
Activities of daily
living
No No No No No NA No
Behavioral problems No Yes
(I2 = 55 %)
No Yes
(I2 = 66 %)
No NA No
Overall assessment No No No Yes
(I2 = 48 %)
No NA No
An I2 value of 0 % indicates no heterogeneity and 25, 50 and 75 % the thresholds for low, moderate and high heterogeneity respectively
NA not applicable (no heterogeneity calculable with only one study)
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giving an assessment of memantine outside the licensed
indication, or to exclude these trials and therefore moderate
patients.
5.1 Disease Severity
We have considered the impact of the selected patients, in
terms of severity and concomitant treatment, on the meta-
analysis results. While patient selection can go some way
to explaining differences in outcomes, for example the
effect of memantine on function in mild to moderate versus
moderate to severe patients, these factors do not explain all
observed variations. This is highlighted by the interaction
analyses on the Winblad meta-analysis; in moderate to
severe patients there was no significant interaction between
treatment effect and the baseline factors of disease severity
or use of AChEIs. This supports the strategy of combining
data from the six clinical trials.
5.2 Weighting of Negative Trials
Possible explanations for differences in results could be
related to other factors, such as insufficiently powered sub-
group analyses or the relative weight of negative studies. For
example, the PenTAG monotherapy analysis reported no
significant results for memantine in cognition in moderately
severe to severe patients. When compared to the Cochrane
review, which included the same severity population but
included combination study MEM-MD-02, the results were
significant. This can be explained by the different weights in
each analysis given to study MEM-MD-01 for which no
significant benefit for memantine was reported. The chal-
lenge in understanding the differences in outcomes between
memantine studies results from there being no active treat-
ment comparator arm. It is therefore impossible to ascertain
whether nonsignificant results are a result of negative trials,
where the nonsignificant difference between active treat-
ment and placebo is a consequence of the treatment itself, or
a failed trial where the inability to show significance is due to
flaws in the trial design and/or execution.
5.3 Selection of Trials
The selection of trials is also key. Given the disparity in
results between individual studies for memantine, when a
lower number of trials are included in the meta-analysis,
the impact of extreme results in a given study on overall
heterogeneity is higher. Broader inclusion criteria are more
likely to give a homogenous result reflective of the true
effect of memantine. For moderate to severe patients, this
is highlighted in the Winblad and IQWiG analyses, which
included all trials across the licensed indication and were
associated with low heterogeneity.
5.4 Baseline Behavioral Disorders
It is also worth noting that the efficacy of memantine has
been reported in patients with agitation, aggression, or
psychosis at baseline [28]. In fact, the efficacy in this
population was greater than that reported in patients
without these symptoms at baseline across all domains and
this may further explain differences between analyses
dependent on the proportion of patients with these behav-
ioral disturbances at baseline [29].
Of the domains reviewed, the results for behavioral
disorders are the most disparate and it is challenging to
understand what drives these differences. Generally, in
patients with behavioral disturbances, neuropsychiatric
symptoms are chronically present. However, individual
symptoms often show an intermittent course and patients
may periodically experience different symptom severities
[30, 31]. This makes quantifying behavioral symptoms and
assessing their change over time difficult. The scale used to
assess the behavioral disorders, the neuropsychiatric
inventory (NPI) [32, 33], considers 12 types of different
and sometimes antagonistic neuropsychiatric behaviors.
Each behavior is scored in terms of frequency and severity,
and these are multiplied to give a total score. The calcu-
lation of NPI total score is such that two patients with very
different profiles in terms of behavioral symptoms could
have similar NPI scores. The heterogeneity of AD and the
scoring system of the NPI means that this can be difficult to
interpret, and may explain the disparate meta-analysis
results. It is also worth noting that none of the memantine
studies included NPI as a primary efficacy endpoint,
potentially leading to problems of powering. Two studies
(MEM-MD-10 and MEM-MD-02) did demonstrate a sig-
nificant effect of memantine compared to placebo for NPI
[14, 15].
Given the heterogeneity of behavioral symptoms in AD,
a global score may not be the best approach. A more
appropriate method could be to analyze different types of
behavioral problems separately. This was performed in a
pooled analysis of individual patient data that considered
changes from baseline in both total NPI score and in single
NPI items [34], in moderate to severe AD patients treated
with memantine in the six pivotal trials. At 24 to 28 weeks,
memantine was reported to be associated with significant
improvements versus placebo in both total NPI score
(p = 0.008) and the individual symptoms of delusions
(p = 0.001), agitation/aggression (p = 0.001), and irrita-
bility/lability (p = 0.005). At this time point, memantine
was not associated with a significant impact on the other
nine individual NPI single items. This highlights that when
the NPI total score is analyzed, there is substantial data
contributing to the score that is not significant and con-
tributes ‘‘noise’’ to the system. The improvements observed
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with memantine in agitation and aggression were particu-
larly significant, because these are not only among the most
common behavioral symptoms of AD, but are most com-
monly associated with emotional strain for caregivers,
rapid disease progression, and early institutionalization
[34, 35]. Another important analysis relates to the emer-
gence of symptoms in subsets of patients asymptomatic for
the individual NPI items at baseline. At week 24/28, sig-
nificantly more memantine-treated patients remained
asymptomatic in terms of agitation/aggression, irritability/
lability, and night-time behavior compared to placebo.
5.5 Additional Trials
In addition to clinical trials presented here that have been
included in meta-analyses, more recent clinical trials have
been completed: Asubio IE-2101 [36], Forest MEM-MD-
22 [37], Lundbeck 10112 [38], and Lundbeck 10158 [39].
These included both positive and nonconclusive studies.
An update of the Winblad meta-analysis including three of
these additional clinical trials (Asubio IE-2101, Forest
MEM-MD-22, Lundbeck 10112) has been performed [29].
Conclusions were that inclusion of the additional trials had
no influence on the results and all conclusions remained
unchanged.
Across all domains, the efficacy of memantine com-
pared to placebo has been demonstrated in individual
clinical trials. This highlights that the benefits reported in
pooled analyses represent a real effect of memantine
therapy and are not an artefact of pooled data.
6 Conclusions
The efficacy of memantine was consistently demonstrated
versus placebo across the cognition, ADL, and overall
assessment domains within the licensed indication. Benefit
of memantine on behavioral symptoms was also demon-
strated in several meta-analyses, although a simple analysis
of the total NPI score might not be sufficient to have a
comprehensive view on the nature of this benefit. The
meta-analyses of memantine reported here highlight that
the methodological approach has an impact on the results,
but differences between meta-analyses cannot be fully
explained by the selection of the trials and analysis method.
Overall, individual clinical trial results and the consistency
of meta-analyses results demonstrate that memantine rep-
resents a valuable treatment option in AD.
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